Adaptive NKG2C+ NK cells expanded by our method, besides maintaining their distinctive molecular traits, such as a low expression of FcεRγ, displayed high ADCC abilities in response to opsonized tumor targets, a requisite mandatory for mAb-mediated immunotherapies. The gene discussed is KLRC2; the disease is neoplasm.